Patents by Inventor Toshihide Yamashita
Toshihide Yamashita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230090965Abstract: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating dementia selected from diabetic dementia and vascular dementia.Type: ApplicationFiled: January 15, 2021Publication date: March 23, 2023Applicants: OSAKA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Toshihide YAMASHITA, Takahide ITOKAZU, Hiroki UNO, Hirokazu ISHIDA
-
Publication number: 20230055626Abstract: This invention provides an agent comprising a RGMa inhibiting substance for preventing or treating diabetic autonomic neuropathy.Type: ApplicationFiled: January 15, 2021Publication date: February 23, 2023Applicants: OSAKA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATIONInventors: Toshihide YAMASHITA, Takahide ITOKAZU, Hiroki UNO, Hirokazu ISHIDA
-
Patent number: 11407826Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.Type: GrantFiled: February 26, 2020Date of Patent: August 9, 2022Assignee: Osaka UniversityInventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
-
Publication number: 20210277098Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: ApplicationFiled: May 17, 2021Publication date: September 9, 2021Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori HASHIMOTO, Toshihide YAMASHITA
-
Patent number: 11008388Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: GrantFiled: March 19, 2019Date of Patent: May 18, 2021Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori Hashimoto, Toshihide Yamashita
-
Publication number: 20200190184Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.Type: ApplicationFiled: February 26, 2020Publication date: June 18, 2020Inventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
-
Patent number: 10640768Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.Type: GrantFiled: April 10, 2018Date of Patent: May 5, 2020Assignee: OSAKA UNIVERSITYInventors: Toshihide Yamashita, Yasufumi Hayano
-
Patent number: 10611834Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.Type: GrantFiled: February 10, 2016Date of Patent: April 7, 2020Assignee: Osaka UniversityInventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
-
Publication number: 20190270799Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: ApplicationFiled: March 19, 2019Publication date: September 5, 2019Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori HASHIMOTO, Toshihide YAMASHITA
-
Patent number: 10293026Abstract: An object of the present invention is to provide a pharmaceutical preparation that can promote the proliferation of oligodendrocyte precursor cells to effectively prevent or treat a demyelinating disease. FGF21 acts to promote the proliferation of oligodendrocyte precursor cells, and thus, the administration of FGF21, DNA encoding FGF21, an FGF21 production-promoting substance, and/or FGF21-producing cells is effective for preventing or treating a demyelinating disease.Type: GrantFiled: September 8, 2015Date of Patent: May 21, 2019Assignee: Osaka UniversityInventors: Rieko Ikeda, Mariko Kuroda, Toshihide Yamashita
-
Patent number: 10287346Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: GrantFiled: April 27, 2016Date of Patent: May 14, 2019Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori Hashimoto, Toshihide Yamashita
-
Publication number: 20180230469Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.Type: ApplicationFiled: April 10, 2018Publication date: August 16, 2018Applicant: OSAKA UNIVERSITYInventors: Toshihide YAMASHITA, Yasufumi HAYANO
-
Patent number: 9970003Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.Type: GrantFiled: August 11, 2014Date of Patent: May 15, 2018Assignee: OSAKA UNIVERSITYInventors: Toshihide Yamashita, Yasufumi Hayano
-
Publication number: 20180100012Abstract: The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity arid few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.Type: ApplicationFiled: April 27, 2016Publication date: April 12, 2018Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Motonori HASHIMOTO, Toshihide YAMASHITA
-
Publication number: 20180002419Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.Type: ApplicationFiled: February 10, 2016Publication date: January 4, 2018Inventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
-
Publication number: 20170258875Abstract: An object of the present invention is to provide a pharmaceutical preparation that can promote the proliferation of oligodendrocyte precursor cells to effectively prevent or treat a demyelinating disease. FGF21 acts to promote the proliferation of oligodendrocyte precursor cells, and thus, the administration of FGF21, DNA encoding FGF21, an FGF21 production-promoting substance, and/or FGF21-producing cells is effective for preventing or treating a demyelinating disease.Type: ApplicationFiled: September 8, 2015Publication date: September 14, 2017Applicant: Osaka UniversityInventors: Rieko IKEDA, Mariko KURODA, Toshihide YAMASHITA
-
Patent number: 9751938Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: GrantFiled: May 9, 2016Date of Patent: September 5, 2017Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide Yamashita, Takekazu Kubo
-
Publication number: 20160244517Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: ApplicationFiled: May 9, 2016Publication date: August 25, 2016Applicant: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide YAMASHITA, Takekazu KUBO
-
Publication number: 20160202269Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.Type: ApplicationFiled: August 11, 2014Publication date: July 14, 2016Applicant: OSAKA UNIVERSITYInventors: Toshihide YAMASHITA, Yasufumi HAYANO
-
Patent number: 9334323Abstract: Provided is a T cell activation inhibitor containing an RGM inhibiting substance such as an anti-RGM neutralizing antibody and the like as an active ingredient. The T cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by T cell activation. In addition, a T cell activation inhibiting substance can be screened for by contacting a test substance with RGM and selecting a test substance that lowers the activity level of RGM.Type: GrantFiled: December 8, 2010Date of Patent: May 10, 2016Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Toshihide Yamashita, Takekazu Kubo